에 대한 최신 뉴스 Novo Nordisk (OTC:NONOF) 주식

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

NOVO NORDISK A/S B NEW by Novo-Nordisk A/S

Novo Nordisk AS

NOVO NORDISK ORD

Janus Henderson Global Life Sciences Diversified ADR Managed Account Q2 2024 Commentary

EXG: Earn A 9.32% Yield And Keep Your Equity Exposure With This CEF

Janus Henderson Responsible International Dividend Fund Q2 2024 Commentary

Roche: The Devil Is In The Details - Obesity Data Presentation Disappoints

Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data

Evotec, Novo Nordisk forms technology development partnership for stem cell-based therapies

Evotec, Novo Nordisk form technology development partnership for stem cell-based therapies

Hartford International Growth Fund Q2 2024 Commentary

Consider Buying Potential Takeover Target Altimmune

Can Novo, Lilly take credit for U.S. obesity rate decline?

AAPL

ABBV

AMGN

AMZN

ASML

ASMLF

ASND

AVDL

AXAHF

AXAHY

AZNCF

BHVN

CMPGF

CMPGY

DTEGF

DTEGY

DTGHF

DTRUY

EADSF

EADSY

ETNB

FDMT

FLUT

GMED

GOOG

GOOGL

INSM

MDTTF

MSFT

NONOF

NSRGF

NSRGY

NVDA

NVSEF

PDYPY

RBSPF

RELX

RHHBF

RHHBY

RHHVF

RLXXF

RYAAY

RYAOF

SAFRF

SAFRY

SBGSF

SBGSY

SDVKF

SDVKY

SNYNF

SPOT

SRPT

SSNLF

TCEHY

TCTZF

TLTZF

TLTZY

TOELF

TOELY

TSMWF

UNLYF

URTH

UTHR

VKTX

VRTX

ZFSVF

ZURVY

Novo Nordisk

Comments

Novo Nordisk

뉴스

에 대한 최신 뉴스 Novo Nordisk (OTC:NONOF) 주식

뉴스

파트너 / 기고자

벤징가 글로벌